General information

Announcements(1)

Program

Sessions

Search presentations

Timetable

Tue. Mar 10, 2026

Wed. Mar 11, 2026

Thu. Mar 12, 2026

web_header_en.png

web_icon_ja.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

企画

Profile management

Announcements

Bookmark

Download PDF for print

TR/rTR using human iPS cells for neurodegenerative diseases

On April 9, 2025, the U.S. Food and Drug Administration (FDA) announced a roadmap to phase out animal testing in the evaluation of antibody-based drugs and other products. Subsequently, on April 24, 2025, the U.S. National Institutes of Health (NIH) declared its policy to promote New Approach Methodologies (NAMs)—which incorporate cutting-edge technologies such as human organoids and organ-on-a-chip systems—for human drug evaluation, with the aim of reducing reliance on animal testing.In response to these international trends, it is becoming increasingly important in basic research to advance the use of human tissue models and to integrate complex human biological systems, disease mechanisms, and real-world data. Here we would like to feature a series of comprehensive presentations covering drug discovery, safety assessment, organoid research, and international trends to deepen understanding among participants. In addition, we will discuss the challenges and limitations of non-animal testing approaches and provide a forum to share future perspectives in this rapidly evolving field.

Advancing Human Relevant Physiological Models for Drug Development: Challenges and Future Perspectives

The 103rd Annual Meeting of The Physiological Society of Japan

Presentation Information

[1S06a-01]TR/rTR using human iPS cells for neurodegenerative diseases

Keywords:

Password required to view

Comment